HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a report published on Friday, September 21st. HC Wainwright currently has a $49.00 price target on the biotechnology company’s stock.
“Valuation disconnect continues even when considering a limited set of current assets. Regarding our valuation of XOMA we believe that the current share price is currently disconnected from the underlying value of even just its opportunity from Novartis (NVS; not rated) partnered assets, led by canakinumab (Ilaris).”,” the firm’s analyst wrote.
XOMA has been the subject of a number of other reports. Wedbush reissued an outperform rating on shares of XOMA in a research report on Monday, September 17th. Zacks Investment Research cut shares of XOMA from a buy rating to a hold rating in a research report on Saturday, July 21st. S&P Equity Research reduced their price target on shares of XOMA from $18.74 to $16.26 in a research report on Tuesday, August 14th. ValuEngine lowered shares of XOMA from a hold rating to a sell rating in a research note on Friday, September 7th. Finally, TheStreet upgraded shares of XOMA from a d rating to a c- rating in a research note on Tuesday, June 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $31.32.
Shares of XOMA stock opened at $15.30 on Friday. XOMA has a 52 week low of $14.61 and a 52 week high of $37.25. The company has a market capitalization of $147.36 million, a price-to-earnings ratio of 15.61 and a beta of 2.51. The company has a debt-to-equity ratio of 3.06, a current ratio of 12.46 and a quick ratio of 12.46.
XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). XOMA had a net margin of 43.55% and a return on equity of 379.39%. The company had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $4.57 million. As a group, equities analysts forecast that XOMA will post -1.14 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in shares of XOMA by 151.6% during the second quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock worth $9,373,000 after acquiring an additional 270,437 shares during the period. Northern Trust Corp increased its stake in shares of XOMA by 308.6% during the second quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 51,510 shares during the period. Spark Investment Management LLC acquired a new position in shares of XOMA during the first quarter worth about $904,000. Acadian Asset Management LLC increased its stake in shares of XOMA by 70.4% during the second quarter. Acadian Asset Management LLC now owns 96,051 shares of the biotechnology company’s stock worth $2,006,000 after acquiring an additional 39,672 shares during the period. Finally, Strs Ohio acquired a new position in shares of XOMA during the second quarter worth about $680,000. Institutional investors own 43.60% of the company’s stock.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Further Reading: Asset Allocation and Your Retirement
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.